Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
- PMID: 37649105
- PMCID: PMC10466826
- DOI: 10.1186/s13195-023-01291-w
Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer's disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
Abstract
Background: Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ)42 to detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with higher specificity for Alzheimer's disease (AD). However, whether Aβ42 and amyR have different meanings and whether Aβ40 represents more than an Aβ42-corrective factor remain to be clarified. Our study aimed to compare the ability of Aβ42 and amyR to detect AD pathology in terms of p-tau/Aβ42 ratio and brain glucose metabolic patterns using fluorodeoxyglucose-positron emission tomography (FDG-PET).
Methods: CSF biomarkers were analyzed with EUROIMMUN ELISA. We included 163 patients showing pathological CSF Aβ42 and normal p-tau (A + T - = 98) or pathological p-tau levels (A + T + = 65) and 36 control subjects (A - T -). A + T - patients were further stratified into those with normal (CSFAβ42 + /amyR - = 46) and pathological amyR (CSFAβ42 + /amyR + = 52). We used two distinct cut-offs to determine pathological values of p-tau/Aβ42: (1) ≥ 0.086 and (2) ≥ 0.122. FDG-PET patterns were evaluated in a subsample of patients (n = 46) and compared to 24 controls.
Results: CSF Aβ40 levels were the lowest in A - T - and in CSFAβ42 + /amyR - , higher in CSFAβ42 + /amyR + and highest in A + T + (F = 50.75; p < 0.001), resembling CSF levels of p-tau (F = 192; p < 0.001). We found a positive association between Aβ40 and p-tau in A - T - (β = 0.58; p < 0.001), CSFAβ42 + /amyR - (β = 0.47; p < 0.001), and CSFAβ42 + /amyR + patients (β = 0.48; p < 0.001) but not in A + T + . Investigating biomarker changes as a function of amyR, we observed a weak variation in CSF p-tau (+ 2 z-scores) and Aβ40 (+ 0.8 z-scores) in the normal amyR range, becoming steeper over the pathological threshold of amyR (p-tau: + 5 z-scores, Aβ40: + 4.5 z-score). CSFAβ42 + /amyR + patients showed a significantly higher probability of having pathological p-tau/Aβ42 than CSFAβ42 + /amyR - (cut-off ≥ 0.086: OR 23.3; cut-off ≥ 0.122: OR 8.8), which however still showed pathological values of p-tau/Aβ42 in some cases (cut-off ≥ 0.086: 35.7%; cut-off ≥ 0.122: 17.3%) unlike A - T - . Accordingly, we found reduced FDG metabolism in the temporoparietal regions of CSFAβ42 + /amyR - compared to controls, and further reduction in frontal areas in CSFAβ42 + /amyR + , like in A + T + .
Conclusions: Pathological p-tau/Aβ42 and FDG hypometabolism typical of AD can be found in patients with decreased CSF Aβ42 levels alone. AmyR positivity, associated with higher Aβ40 levels, is accompanied by higher CSF p-tau and widespread FDG hypometabolism.
Keywords: Alzheimer’s disease; Amyloid beta 40; Amyloid beta 42; Amyloid beta 42/40 ratio; Cerebrospinal fluid biomarkers; Fluorodeoxyglucose-positron emission tomography; Phosphorylated-tau.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.Alzheimers Res Ther. 2021 Jan 12;13(1):22. doi: 10.1186/s13195-020-00767-3. Alzheimers Res Ther. 2021. PMID: 33436035 Free PMC article.
-
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.J Prev Alzheimers Dis. 2022;9(3):491-498. doi: 10.14283/jpad.2022.27. J Prev Alzheimers Dis. 2022. PMID: 35841250
-
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.Alzheimers Res Ther. 2022 Apr 26;14(1):60. doi: 10.1186/s13195-022-01003-w. Alzheimers Res Ther. 2022. PMID: 35473631 Free PMC article.
-
A systematic review with meta-analysis to assess Alzheimer's disease biomarkers in adults with or without obstructive sleep apnoea.Int Orthod. 2023 Dec;21(4):100814. doi: 10.1016/j.ortho.2023.100814. Epub 2023 Sep 28. Int Orthod. 2023. PMID: 37776696
-
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.Curr Clin Pharmacol. 2008 May;3(2):123-31. doi: 10.2174/157488408784293723. Curr Clin Pharmacol. 2008. PMID: 18700307 Review.
Cited by
-
Constitutive NOS Production Is Modulated by Alzheimer's Disease Pathology Depending on APOE Genotype.Int J Mol Sci. 2024 Mar 27;25(7):3725. doi: 10.3390/ijms25073725. Int J Mol Sci. 2024. PMID: 38612537 Free PMC article.
-
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.Nat Med. 2025 May;31(5):1592-1603. doi: 10.1038/s41591-025-03565-2. Epub 2025 Mar 31. Nat Med. 2025. PMID: 40164724 Free PMC article.
-
Sleep spindles and slow oscillations predict cognition and biomarkers of neurodegeneration in mild to moderate Alzheimer's disease.Alzheimers Dement. 2025 Feb;21(2):e14424. doi: 10.1002/alz.14424. Epub 2025 Jan 29. Alzheimers Dement. 2025. PMID: 39878233 Free PMC article.
-
CSF Amyloid-β42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism.Mol Brain. 2025 Jul 1;18(1):55. doi: 10.1186/s13041-025-01229-3. Mol Brain. 2025. PMID: 40597399 Free PMC article.
-
Olive Oil Industry By-Products as a Novel Source of Biophenols with a Promising Role in Alzheimer Disease Prevention.Molecules. 2024 Oct 12;29(20):4841. doi: 10.3390/molecules29204841. Molecules. 2024. PMID: 39459209 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical